

Review

# Lipofuscin as the Main Driving Force of Current Age-Related Disease: Justification and Strategies for Removal

Michael Renteln

University of Würzburg (Germany)

\* Correspondence: Michael Renteln; E-mail: mrenteln@gmail.com

**Abstract:** Lipofuscin is indigestible garbage that accumulates in the autophagic vesicles and cytosol of post-mitotic cells with age. Drs. Brunk and Terman postulated that lipofuscin accumulation is the main or at least a major driving factor in aging. They even posited that the evolution of memory is the reason why we get lipofuscin at all, as stable synaptic connections must be maintained over time, meaning that the somas of neurons must also remain in the same locale. In other words, they cannot dilute out their garbage over time through cell division. Mechanistically, their position certainly makes sense given that rendering a large percentage of a post-mitotic cell's lysosomes useless must almost certainly negatively affect that cell and the surrounding microenvironment. Here, I explore the possibility that the accumulation of lipofuscin to some extent underlies all other categories of age-related damage as defined by Dr. Aubrey de Grey. I do not think that lipofuscin removal will reverse/prevent all forms of aging, just the major component facing us currently. In this piece, I will review what is known about lipofuscin accumulation from evolutionary and mechanistic standpoints and discuss ways of removing it from non-dividing (or slowly-dividing) cells.

**Keywords:** Anti-aging therapy; lipofuscin; SENS; TFEB; intracellular microbe; and synthetic chemotaxis

---

## Introduction:

Biological aging is a complex molecular process that takes place over time in all organisms. However, organisms have evolved mechanisms to repair various forms of age-related damage. For example, DNA repair enzymes exist that can fix damage in nuclear DNA. Mitophagy enables the degradation of damaged mitochondria. The immune system, when one is young at least, eliminates at least some proportion of one's senescent cells.

Years ago, Dr. Aubrey de Grey posited that there are seven types of damage that accumulate with age in the human body. These include extracellular aggregates, senescent cells, extracellular matrix stiffening, intracellular aggregates, mitochondrial mutations, cancerous cells, and cell loss/tissue atrophy. He devised a strategy to eliminate each form of damage from the body, called Strategies for Engineered Negligible Senescence (SENS) [1]. He is of the belief that all seven categories must be addressed before substantial life extension can be attained.

However, I believe that one of his categories, i.e., intracellular aggregate accumulation, actually underlies many of the other categories of damage - and that the removal of indigestible lysosomal garbage (lipofuscin) could, by itself, substantially extend the human lifespan. It could serve to substantially reverse aging and also prevent it (if the therapy were applied perhaps every decade or so to individuals starting at an age of ~30).

There are two arguments for lipofuscin removal being the most important goal of anti-aging science currently. One is evolutionary and one is mechanistic.

### **Evolutionary argument:**

In nature, there are only a handful of organisms that can be said to be essentially biological immortal. *Hydra vulgaris* (i.e., *magnipapillata*) is one of such organisms, and the reason for this might be that its indigestible garbage is essentially released from its body over time. It has three cell lineages - ectodermal epithelial, interstitial, and endodermal epithelial. All the epithelial cells in its body column are stem cells that continuously divide - displacing cells toward its extremities. The cells at the extremities slough off eventually [ii, iii]. In terms of the interstitial lineage, the differentiated cells that its stem cells produce are closely associated with epithelial cells and so are continuously displaced as well. This is a convenient way to dispose of lipofuscin - i.e., through dilution and cell shedding. However, continuous replacement of neurons may not allow for the stable inter-neuronal interactions required for long-term memory [iv]. Lobsters continually grow throughout life; their fully differentiated cells express telomerase, allowing them to keep dividing as needed [v]. This includes the cells of their central nervous system, which allows for adult neurogenesis [vi]. They also shed their shells periodically. Thus, the same logic appears to apply to them. However, their growth process does not appear to be fast enough to prevent lipofuscin from accumulating over time [vii]. Notably, lipofuscin accumulation in eyestalk ganglia [viii] is used as a gauge of biological age in lobsters (and myocardial lipofuscin accumulation can be used a marker of chronological age in humans [ix]). Lobsters can retain memories, but only for a short time span [x]. Naked mole rats are also very long lived, and it has been shown that they have unusually active autophagic systems [xi, xii] (in addition to better anti-cancer defenses [xiii]). Even with better autophagy, naked mole rats still do accumulate lipofuscin in their post-mitotic tissues [xiv].

It appears as though all animals that age, e.g., flies [xv], worms [xvi, xvii], lobsters, naked mole rats, mice [xviii], non-human primates [xix], and humans [xx] accumulate lipofuscin in their post-mitotic tissues. None of the aforementioned organisms seem to possess any evolutionarily "built-in" ways of exporting the lipofuscin that accumulates in their post-mitotic cells from their bodies, presumably because that would be an unnecessary expenditure of energy in light of procreation. Export from the post-mitotic cells themselves is possible through exocytosis [xxi], exosome/microvesicle secretion, or secretory autophagy. That part is not too energetically costly. However, from *in vitro* studies, it does not seem as though lipofuscin is exported from post-mitotic cells very often [xxii]. It also has never been observed *in vivo* [xxiii]. More importantly, if exported *en masse*, there would be nowhere for the garbage to go except to be picked up by tissue-resident phagocytes, which themselves become bloated with lipofuscin - probably mostly from damaged molecules deriving from their own metabolic processes [xxiv, xxv]. (Transfer of lipofuscin to tissue-resident phagocytes through tunneling nanotubes or partial cell fusion is also theoretically possible.) Finally, I have seen no evidence in the literature that tissue-resident phagocytes - full of lipofuscin or not - are able to efficiently leave the body through migration to the gastrointestinal tract, skin, or lungs.

### **Mechanistic argument:**

Lipofuscin can eventually occupy a large portion of the cytoplasm in certain cell types. If it reaches a critical level that negatively affects cellular metabolism in a large enough number of cells in a tissue, it could not only cause pathology, but also cause a downward spiral of functionality due to an exponential increase in the whole-body accumulation of the other six categories of age-related damage as defined by Dr. Aubrey de Grey. For example, damaged mitochondria will not be mitophagized as rapidly and may then start to accumulate. Beta-amyloid that is normally degraded may sit around for longer in the extracellular space and begin to form plaques. Senescent cells may start to accumulate if the tissue-resident immune cells are rendered inert either by phagocytosis of ejected lipofuscin or more likely, the general non-functionality of

the parenchymal cells around them leading to dilapidation of the extracellular matrix. Cancer will be more likely to form if many microenvironments throughout the body are corrupted. Similarly, stem cell niche corruption may prevent them from replicating efficiently to replenish tissues. And, it is clear that with the extracellular matrix not being tended to properly by its resident cells, stiffening due to cross-links may occur more frequently than they can be cleaved.

It has been argued that lipofuscin is inert. Recently, more researchers are starting to look into whether it may in fact play a pathological role inside a given cell [xx, xxvi, xxvii]. Even if the damaged molecules are mostly sequestered within lysosomes and are not actively harmful to the cell, the fact that many lysosomes become full of garbage and therefore are almost surely unable to perform their normal functions nearly as well just logically seems as though it must be a major problem for the cell. Along these lines, lipofuscin-loaded human fibroblasts display reduced autophagy and decreased survival when exposed to amino acid starvation [xxviii]. If a critical threshold is reached in enough cells in a tissue, e.g., the brain, it clearly would be problematic.

With regard to short-lived species, like mice and rats, lipofuscin may not have enough time to accumulate to pathological levels before they die of cancer. It is estimated that 50-90% of aged mice die of cancer [xxix]. Even still, it was shown that in the cerebral cortex neurons of lamina Vb in 630-700-day old rats, lipofuscin occupied 23% of the soma volume [xxx, xxxi]. This could still certainly have a negative physiological effect. Unsurprisingly, we do see a cognitive decline in mice with age [xxxii]. However, even the oldest mice do not develop age-related neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis [xxxiii]. Ostensibly, they simply do not live long enough for sufficient build-up of lipofuscin in their neurons. Other conditions like age-related macular degeneration and sarcopenia do occur in mice, but whether their most severe cases are as bad as the most severe human cases is unclear to me. It is also possible that some mouse tissues accumulate lipofuscin more rapidly than others due to cell type differences in metabolic rates, etc. Some types of human neurons, for example, have not accumulated much lipofuscin by the time others are nearly full [xxxiv].

With regard to humans, it has been demonstrated that multiple neuronal cell subtypes become densely packed with lipofuscin granules with age [xxxv, xxxvi, xxxvii]. In large motor neurons of centenarians, lipofuscin constitutes up to 75% of total cytoplasmic volume [xxxviii]. Other post-mitotic cell types also accumulate substantial amounts of lipofuscin [xxxix, xl, ix]. Lipofuscin-laden lysosomes are often much larger than typical lysosomes. The typical size of a lysosome in a fed, unaged cell is ~100 nm-500 nm in diameter [xli]. In contrast, lipofuscin granules are generally 1-5 microns in diameter [xxxviii].

Also, it should be noted that many studies of lipofuscin have relied upon autofluorescence measurements [xlii], but lipofuscin is also very heterogeneous with regard to its structure and composition between different species, tissues, perhaps even cells of the same type, and when found at different concentrations [xx]. Thus, it seems as though relying on a specific wavelength range to visualize a cell's lipofuscin deposits may not be prudent.

If one could remove the lysosomes from laden macrophages stuck at plaques in artery walls, the plaques may eventually regress, given a healthy diet and sufficient exercise as well [xliii]. Similarly, with regard to extracellular plaques like beta-amyloid plaque, Le Chatelier's principle may apply. If there are fewer of the soluble protein monomers in solution in that area, the solid mass may dissolve back into solution. Parenchymal cells devoid of lipofuscin could endocytose monomers; as they are degraded, the extracellular plaques could start to dissolve and be taken up as monomers as well - for subsequent degradation. Tau tangles would be autophagocytosed and degraded as well. For the elderly, multiple rounds of lysosomal

clearance may be necessary to achieve full results - because, for example, defective mitochondria could have accumulated that will be mitophagized after the initial lipofuscin clearance, which may then become lipofuscin inside the lysosomes due to extensive damage of the mitochondrial membranes by free radicals.

### **Removal strategies *in vivo* (on a cellular basis):**

The simplest way to prevent lipofuscin accumulation is to prevent the excessive uptake of biomolecules from external sources via caloric restriction [xliv]. Caloric restriction triggers upregulated autophagy [xlv], meaning that reversal and prevention are possible to some degree through this method. Exercise also increases the degradative capacity of our cells [xlv]. But, of course, these two methods alone are not enough to reverse/prevent aging in a truly substantial manner.

Dr. Aubrey de Grey, an anti-aging pioneer, first introduced me to the concept of lipofuscin through his 2005 TED talk and book that he co-authored with Michael Rae, "Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime [xlvii]." He proposed a way of eliminating it from the body involving "xenocatabolism". It is based on his realization that lipofuscin, which is typically fluorescent, must be eliminated from human corpses by microbial enzymes, or else graveyards would glow in the dark. He postulated that we can co-opt enzymes from soil bacteria and fungi and install them in our cells to degrade our lipofuscin [xlviii]. However, I do not believe this will be feasible in our lifetimes at least, as lipofuscin is quite heterogeneous - it varies widely in composition between cell types and even cells of the same type, potentially [xlix]. It also varies in composition between different individuals, probably in part due to differences in diet.

Thus, it would likely require an inordinate number of microbial enzymes to degrade the majority of our lipofuscin, almost all of which would still have to be discovered, evolved, or rationally-designed - and many of them may be toxic to our cells. There are some molecular species that seem to be major contributors to lipofuscin or lipofuscin's toxic effects at least in some cell types, like the fluorophore A2E (retina) [l] and the oxysterol 7-ketocholesterol (throughout the body - especially atherosclerotic plaques and the retina) [li], but we cannot neglect other organs or tissues, or they will fail and we will die anyway. It is worth looking into to see if there are major lipofuscin constituents present across a wide variety of cell types that would be very good targets. But it is unlikely, at least in my mind, that a small number of enzymes will be sufficient to degrade the majority of our lipofuscin deposits.


TFEB is the master regulator of autophagy, and its overexpression can increase lysosomal acidity and boost lysosomal hydrolase levels in lysosomes, which could help to shrink existing lipofuscin deposits in lysosomes. Here, it is important to draw a distinction between "false" and "true" lipofuscin. False lipofuscin would be any intracellular garbage that can be digested by cellular machinery if said machinery is maximally expressed. True lipofuscin is that which is indigestible by cells no matter how they are transcriptionally manipulated. But TFEB (i.e., HLH-30) overexpression only grants a 15-20% increase in lifespan for *C. elegans* [lii]. Presumably this is because lipofuscin still accumulates in the intestinal cells over time, even with HLH-30 overexpression. For this truly indigestible garbage, TFEB could still be of use. It also induces the exocytosis of lysosomal contents through fusion of the lysosomal and plasma membranes.

One problem with boosting endogenous exocytosis processes is that they may lose potency with age; oxidatively warped lipids from lipofuscin may insert themselves into the membranes of the lysosomes that contain them and prevent efficient fusion with the plasma membrane. The main problem, however, is that the two most well-known inducers of lysosomal exocytosis,  $Ca^{2+}$  and TFEB, do not induce a substantial amount of exocytosis - even in youthful cells [liii, liiv]. Perhaps over


time, TFEB could work well enough to exocytose all a post-mitotic cell's lipofuscin, but other cellular mechanisms may need to be combined with TFEB for truly effective exocytosis - and there may be cell type differences in what machinery is required. A small molecule was shown to induce some lipofuscin exocytosis in monkey retinal pigment epithelial cells, which are important in macular degeneration [xxiii]. A final issue is that with lysosomal exocytosis, lipofuscin granules may break apart and/or get caught in various parts of the extracellular matrix - causing a problem by being there. The lipofuscin could also at least eventually be taken up by the same cells that ejected it, neighboring cells that need to be cleared of garbage themselves, or tissue-resident macrophages. It's probably better for the lipofuscin to be inside an intact vesicle that can prevent re-uptake - only to be picked up by bioengineered macrophages.

Lipofuscin could also theoretically be exported from post-mitotic cells through microvesicular secretion of lysosomes or by transferring lysosomes through tunneling nanotubes (TNTs) to bioengineered macrophages delivered to their locale. (However, the diameter of some lipofuscin-laden lysosomes may be too great for them to be transferred through TNTs.) Secretory autophagy may also be relevant here [lv, lvi]. Secretory autophagy utilizes autophagosomes, which are double-membrane vesicles. Perhaps a pathway involving the exocytosis of lysosomes engulfed in single-membrane vesicles could also be possible [lvii].

A.



B.






Figure 1. **Lipofuscin-laden lysosome removal from a non-dividing or slowly-dividing cell using a “trash-collecting” microbe.** A) The intracellular microbe enters the target post-mitotic cell. B) The intracellular microbe escapes the vacuole. C3. The intracellular microbe phagocytoses a lipofuscin-laden lysosome. Of course, not all of a target cell’s lysosomes may be full of lipofuscin. But over time, through random chance, even with new lysosomes being generated naturally or via TFEB induction - many if not most of the garbage-filled lysosomes will be removed. C4. Amoebae that have picked up indigestible lysosomal cargo re-enter a vesicle. C5. Full amoebae are ejected from the cell via exocytosis.

Instead of trying to determine which combination of proteins would promote each post-mitotic cell type to efficiently rid itself of its lipofuscin, an intracellular microbe could be harnessed to enter post-mitotic cells and engulf lipofuscin-laden lysosomes directly, then escape the cell. The smallest white blood cell with phagocytic properties has a diameter of 12-15 microns (neutrophils). Some post-mitotic cells have a diameter of around 10 microns. Thus, instead of trying to bioengineer a leukocyte to be intracellular, it might be best to use a micro-organism with a diameter of ~3 microns so that they can enter the cell and engulf lysosomes that have grown to a relatively large size due to lipofuscin accumulation. If the micro-organism could expand (i.e., if it had a ruffled membrane) to accommodate even larger cargo, that would be ideal. Perhaps phagocytic bacteria (~4-5 microns in diameter) [lviii] would be easier to work with than amoebae in terms of having them survive inside host cells and not damage said cells. However, one micro-organism of the appropriate size and with phagocytotic properties is an amoeba known as *Massisteria voersi* [lix].

It might be necessary to prevent the attempted digestion of the phagocytosed material - in order to prevent metabolic failure of/cytotoxicity to the microbe. Also, a mechanism may need to be in place that could prevent phagocytosis of more than one target. Finally, perhaps a mechanism should be put in place to induce growth [lx], detachment, or lysis (to avoid microbial stress-mediated detrimental effects like chromosomal instability or, potentially, toxin secretion) upon phagocytosis frustration - possibly via a timer-based mechanism involving a temporal promoter cascade as in early, intermediate, and late viral gene expression.

An even smaller microbe may be required to treat certain cells; the somas of cerebellar granules cells, for example, are only around 5 microns in diameter. Perhaps a single microbe could treat all target cells if it can identify smaller human cell

types based on surface proteins - inducing shrinking of the microbe if it recognizes a smaller human cell type [lx]. (Being smaller initially might help with cell entry; the microbe could potentially grow a bit after entering a target cell and escaping the endosome. Encountering a smaller cell, plausibly with smaller lysosomes in general - even with lipofuscin accumulation - could trigger a counting mechanism wherein it picks up more than one lysosome in the target cell [lxi]. This may increase the “cleaning” efficiency of this approach.)

Non-replicating intracellular bacteria can be rapidly generated by introducing into them a plasmid encoding the *dnaA* gene that has a temperature sensitive origin of replication and then deleting the *dnaA* gene from the bacterial genome [lxii]. When the temperature is increased, the bacteria will lose the plasmid and become non-replicating; ampicillin can then be added to the culture to lyse the dividing cells while sparing the non-dividing cells. However, those bacteria elongate substantially and may have other metabolic abnormalities. (Moreover, it is plausible that bacteria that are so elongated could potentially have trouble entering certain target cells.) Alternatively, RelA overexpression induces the large scale production of pppGpp and ppGpp. These two molecules are known together as (p)ppGpp, and they are known to drastically slow bacterial growth [lxiii, lxiv]. Thus, (perhaps truncated) RelA overexpression could be the baseline state in the trash-collecting intracellular bacteria [lxv]. However, some amount of RelA may be necessary for the vector to survive in host cells [lxvi].

Only two genes are required to change a normally extracellular bacterium to an intracellular bacterium, an invasin gene and the listeriolysin O gene from *Listeria monocytogenes* [lxvii]. Perhaps those two could be utilized here as well for an amoeba. Moreover, ActA could potentially be utilized to promote intracellular movement of the amoebae [lxviii]. The phagocytic receptors on the amoebae would be redirected to LAMP-1, a lysosomal transmembrane protein. The amoebae could also secrete Bcl-2 to prevent stress-induced apoptosis of host cells - in case its presence inside the cell is excessively detrimental to the metabolism of that cell [lxix]. However, further bioengineering may certainly be necessary to prevent host cell cytotoxicity.

The amoebae could be bioengineered to phagocytose lysosomes only, perhaps via selective recognition of targets heavily decorated with LAMP-1 [lxx]. (If LAMP-1 is too non-specific in terms of its localization on other autophagic/endocytic vesicles, an AND-gated receptor system could certainly be developed - similar to SynNotch [lxxi].) After an amoeba binds its target, there could then be a pause using a synthetic gene circuit like a temporal promoter cascade, allowing for the engulfment process to proceed and be completed. Then, the amoebae would escape via extrusion, budding, actin-mediated protrusion [lxxii], ejection, expulsion, or exocytosis [lxxiii]. Notably, *F. tularensis*, an intracellular bacterium, is known to re-enter the endocytotic compartment after cytoplasmic replication - perhaps at least in part due to its ability to then be exocytosed, spreading to neighboring cells [lxxiv]. A microbe with a T3SS might be able to translocate proteins across the vesicle into the cytoplasm to force its exocytosis. There is a *Mycobacterium tuberculosis* surface protein that promotes engulfment of the bacteria into LC3-associated autophagosomes [lxxv].

(Of course, prior to an amoeba engulfing a lysosome, autophagosomal engulfment must be prevented. ActA would help - through motility-dependent and motility-independent mechanisms [lxxvi, lxxvii]. Also, expression of USP30 [lxxviii, lxxix] on the surface of the amoebae could help. Production of at least the former protein should be halted when the amoeba has engulfed its target and needs to be autophagocytosed.)

TFEB expression [lxxx] by the microbes prior to engulfment - using a time delay synthetic gene circuit, could help to consolidate garbage by promoting autophagosome-lysosome fusion and get most of the lipofuscin in vesicles rather than some of it being free in the cytoplasm. It would also be important to induce TFEB expression after engulfment, but prior to leaving - in order to force the generation of new lysosomes, so the cell is not left at a serious deficit. A small molecule that increases TFEB activity could perhaps alternatively be used instead prior to and periodically throughout treatment - such as the one currently being developed by Genierian. Incorporating TFEB activity would likely increase the overall treatment time, as it would generate new lysosomes that may be targeted by the intracellular microbes, but over time, eventually all the lipofuscin-laden lysosomes would be removed as well - and it seems much safer/like it would lead to a much more thorough "deep clean".

### **Testing the importance of lipofuscin accumulation in aging *in vitro* now:**

In order to test the theory that lipofuscin is the main issue with regard to age-related disease perhaps for the next few hundred years at least, it appears that we must either figure out how to induce a particular post-mitotic cell type (e.g., a neuron derived from an iPSC) to export its garbage using a gene vector or remove its lipofuscin-laden lysosomes with host cell-autonomous means. Then we could see how long it lives in culture as opposed to normal cells of the same type. However, while primary cell cultures often die after a few days-weeks [lxxx], the cause of death may not be related to normal aging. It may instead be related to infection or hyperosmolality due to evaporation of the media [lxxxii]. It was shown, however, that at ~day 25, neurons *in vitro* have an aged phenotype, including dysfunctional mitochondria, higher reactive oxygen species production, and at least one feature of senescence [lxxxiii]. It was also shown that defective autophagy was linked to this senescence-like phenotype - and that aged neurons in culture accumulate lipofuscin [lxxxiv]. Thus, if the lipofuscin were removed from the cells and new, functional lysosomes were introduced exogenously or generated through TFEB, their aged phenotype may reverse.

Another approach would be to study aged skeletal muscle cells that contain large quantities of lipofuscin taken from biopsies of elderly humans [lxxxv]. Their lipofuscin-laden skeletal muscle cells may also eventually die from other causes than normal aging due to culture conditions. But by removing the lipofuscin from those cells, one could at least see if markers of health are restored in the cells; i.e., defective mitochondria could be mitophagized, any cytoplasmic lipofuscin granules could eventually be autophagocytosed and delivered to lysosomes, and a senescence-like phenotype could eventually be reversed.

To get a cell to export its garbage, perhaps one could force lysosomes out to the periphery via JIP4 inhibition [lxxxvi] while overexpressing the VAMP7, Stx4, and SNAP23 [lxxxvii] - and then administer  $Ca^{2+}$  and the calcium ionophore A23187 to the cell to induce fusion of peripheral lysosomes with the plasma membrane [liii]. TFEB would subsequently be overexpressed to induce lysosomal biogenesis [lxxxviii]. This approach could be applicable to many cells in culture. (Other inhibitors like TMEM55B could also be inhibited via siRNA; the concept of inhibiting inhibitors is also clearly applicable to secretory autophagy.)

Another approach that may work and would be applicable to many cells in culture would be to target galectin-8 (or TRIM16 directly) to LAMP-1 while overexpressing Sec22b, Stx3/4, and SNAP23/29 to force the selective encapsulation of lysosomes into an autophagosome destined for secretory autophagy [lxxxix, xc, xci]. Also, autophagosome-lysosome fusion could be cyclically inhibited via small molecule or the SARS-CoV-2 viral protein ORF3a to bias at least nascent autophagosomes toward secretory autophagy [xcii, xciii]. Targeting a plus-end directed motor protein to the cells' autophagosomes would also be of use to move them to the periphery. Furthermore, TRIM16 could potentially be engineered so as not to bind to

mLL-1 $\beta$  or any other native cargo - if necessary. However, TRIM16-mediated secretory autophagy has only been observed in the context of protein cargo, to my knowledge. Thus, I am not sure if this approach will work exactly as described. However, whole organelle secretion is possible via cellular mechanisms [xciv, xcv].

In reality, any protein targeted to LAMP-1 with an LC3-interaction region (LIR) [xcvi] and the ability to bind to Sec22b, in the context of Stx3/4 and SNAP23/29 overexpression, might be able to mediate secretory autophagy of lysosomes.

The efficiency of secretory autophagy for these vesicles specifically could potentially be enhanced by engineering/evolving all the proteins in the pathway to have more affinity for their respective binding partner(s). VEGAS [xcvii] may be of use here to enhance the binding affinity of these proteins - or perhaps coiled coils [xcviii] could simply be added, at least in some cases. One could also overexpress all of the altered proteins. (TFEB overexpression would again be helpful to replenish the cells' lysosomes after each round of export.) This approach of increasing the interaction affinity of all the proteins in the pathway and overexpressing the altered proteins also applies to lysosomal exocytosis.

Two host cell-autonomous means occur to me. Both involve a FluidFM-based approach [xcix]. Every few days or so, a single cell could be injected with large iron particles conjugated with antibodies against LAMP-1. Then, a magnetic field could be applied to cluster the lysosomes to one small area at the plasma membrane. They would then be removed by the needle. TFEB would subsequently be induced from an AAV vector genome in the nucleus via small molecule to replenish the intracellular supply of functional lysosomes. The second means would involve the bioengineered amoebae described before. Amoebae containing large quantities of magnetic nanoparticles could infect or be injected into host cells. They could then engulf the target lysosomes. After giving them some time to do so, a magnetic field could be applied near the cell to cluster them in one small area at the plasma membrane. Then, they could be withdrawn via needle. TFEB again would be utilized here.

#### **Eventual *in vivo* strategy for delivery and pick-up of the “trash-collecting” microbes:**

The only real delivery option that occurs to me involves magnetic control of the carrier macrophages. The phagocytic microbes in the carrier macrophages could contain magnetosomes [c] that allow the carrier macrophage to be driven magnetically into various regions like the brain, the heart, segments of skeletal muscle, etc. [ci, cii].

Eventually, perhaps we can figure out how to transiently alter vascular endothelial gene expression to facilitate the extravasation of carrier macrophages and/or bioengineer the carrier macrophages themselves to be able to very efficiently extravasate systemically (i.e., in the absence of inflammation).

This covers the delivery aspect perhaps, but there is still the issue of pick-up. If a large quantity of bare trash-collecting microbes were to migrate through various tissues to an extraction point, it might severely damage those tissues - as microbes have not adapted to migrate safely through human tissue. It is unclear to me what percentage of the damage we see is due to an inflammatory immune response, however. Recently developed “stealth” microbes [ciii], however, may be able to migrate on their own without incurring damage.

Possibly the most facile approach currently is to utilize phagocytic bacteria delivered via bioengineered macrophages - wherein they do not replicate up to quorum sensing number in the host macrophages. After being delivered to a tissue region magnetically, the macrophages could simply lyse to release their cargo. Then, the bacteria will enter target cells,

engulf target cell lysosomes, and escape non-lytically - possibly in the same way that whole organelles are expelled from cells. Once they have escaped, and the PrfA promoter is no longer functional due to the absence of host cell glutathione [civ], they can lyse the vesicle around them if there is one through LLO secretion [cv] (on a timer-mechanism that stops after a period of time sufficient for vesicle lysis). Alternatively, they can simply swim inside the vesicle [cvi]. In any of the above scenarios, the bacteria could also greatly increase the thickness of their capsules [ciii]. (They could have the capsule from the beginning - but it may interfere with intracellular movement and phagocytosis.)

The thick capsule could shield them from re-entering the same cell or entering neighboring cells, and potentially allow them to migrate safely on their own to the peritoneal cavity via magnetosome-based magnetotaxis [cvii]. There, they could be withdrawn via suction-based laparoscopic removal. I am uncertain if a thick capsule is compatible with migration - it seems likely that an encapsulated bacteria could also be motile. If not, the capsule would still potentially protect them from (re-)uptake by parenchymal cells until the bioengineered macrophages get there and pinpoint their locations via a bacteria-produced small molecule. The bioengineered white blood cells could recognize the membrane surrounding the full amoebae or the amoebae themselves (depending on whether a double-membraned or single-membraned vesicle is used for export) via a T-cell receptor [ ]-type strategy, and that could trigger migration to an extraction point. Perhaps engulfment of the first microbe would trigger a counting mechanism [lxi], and when perhaps ~10 amoebae have been engulfed - the bioengineered white blood cells could be induced to migrate to an extraction point.

Withdrawal of trash-laden, carrier macrophages could be effected by implanting small biodegradable beads that slowly release a chemoattractant molecule [cix] inside small devices that serve as a trap for the bioengineered macrophages, perhaps via conjugation of antibodies to the interior of the trap that target a certain surface protein of the bioengineered macrophages. The extraction point could be laparoscopically-inserted "traps" for the bioengineered white blood cells as I just mentioned, the bloodstream (where they can be filtered out through dialysis), or the intestinal lumen. Magnetism could also be used to draw bioengineered macrophages loaded with magnetic nanoparticles to a singular, intraperitoneal extraction point, where they can be removed laparoscopically.

This strategy for *in vivo* treatment will likely require immunosuppression throughout the duration of the treatment. With regard to the intracellular microbe, perhaps a fully immunologically "stealthed" vector [cx, ciii] can eventually be developed through bioengineering. However, it is also important to note that the microbe could potentially be shielded from the extracellular environment at every step throughout the treatment, leaving only cell-autonomous innate immunity as an issue.

If we test these therapies on mice, perhaps they should also be engineered to be cancer-resistant [cxi, cxii, cxiii, cxiv], although periodic lipofuscin removal would likely help decrease the likelihood of malignant growths occurring. However, by using cancer-resistant mice, we could see significantly improved motor and cognitive functionality with extensive lipofuscin removal - in the absence of possible premature death due to cancer.

### Discussion:

Finally, the reason why I believe a phagocytic intracellular microbe may be the best approach to clear lipofuscin is that they already carry many gene networks capable of allowing entry into a wide variety of mammalian cell types, phagocytosis of micron-sized objects, and non-lytic escape from a wide variety of mammalian cell types. Screens can be performed to identify mutants that are even more adept at these three processes. Identifying or rationally-engineering/evolving proteins that can initiate lysosomal exocytosis, secretory autophagy with regard to lysosomes, or microvesicular secretion

of lysosomes in all the necessary target cell types - may not be particularly facile. Also, all of the protein-based approaches would initiate mass export of lysosomes, which may be detrimental to the patient's health even when done slowly - and especially if done throughout the whole body simultaneously.

Target cell-based mechanisms of lysosomal export would also potentially be taxing for them in terms of membrane lipid dynamics. In contrast, the microbes can enter one at a time and pick up cargo, keeping it encapsulated and theoretically preventing re-uptake by the same cell, neighboring cells, or tissue-resident phagocytes. If the microbe buds from the carrier leukocyte or is secreted through secretory autophagy, it would be delivering lipid contents to a given target cell. It would also engulf the target lysosome using its own membrane lipids. Most importantly, as opposed to requiring random bioengineered macrophage migration in a tissue to collect exported garbage, the bacteria could plausibly migrate on their own to an extraction point - or secrete a small molecule signal that allows bioengineered macrophages to hone in on their locations.

However, a phagocytic microbe-independent strategy could also certainly be possible. For example, there is the option of simply employing intracellular microbe secretion. An extracellular microbe with a T3SS could be delivered to target cells to inject them with effectors (although we may have to bioengineer some of the relevant secretion substrates if they can't be secreted efficiently even after addition of a relevant secretion tag) [cxv]. With these two approaches, the trash-collecting microbes could replicate within the carrier white blood cells up to a moderate copy number [cxvi] - restrained by AI-2-based quorum sensing, perhaps [ ]. The carrier white blood cells could then continuously donate the trash-collecting microbes to target cells via microvesicular secretion, secretory autophagy, transient TNTs, or even partial cell-cell fusion. Here, the macrophages would simply be pre-loaded with magnetic nanoparticles.

The granzyme-perforin pathway was also recently proposed as a protein delivery system [cxviii]. TNT-based delivery [cxix, cxx] and towing of protein-loaded liposomes [cxxi] are also potential protein delivery systems.

Other mechanisms like adding cell-penetrating peptides and/or toxin translocation domains to effector proteins secreted by the bioengineered leukocytes might work, but they might not be very effective - especially if many different proteins must be delivered in moderate-large quantities [cxxii, cxxiii].

Finally, one could employ an DNA or RNA vector delivery system involving a plasmid copy number control-type mechanism. Specifically, bioengineered leukocytes could continuously export copies of a viral vector while wandering around within a target tissue - through a synthetic gene circuit involving Cdc42 [cxxiv] perhaps, magnetotaxis, or both. (One of the proteins the virus normally encodes that is essential for the replication of its DNA would be deleted and expressed by the bioengineered leukocyte. Thus, the viral DNA would be able to replicate exclusively in the nucleus of the leukocyte. It would do so up to a particular copy number - restrained by a plasmid copy number control mechanism [cxxv] - thus providing new genomes for packaging in subsequently secreted virion particles while preventing the leukocyte from being overwhelmed.) Superinfection exclusion (SIE) [cxxvi, cxxvii] and maybe a synthetic gene circuit for network-dosage compensation [cxxviii] should be employed when continuous gene vector export is desired. Clinicians could visualize how many of a patient's cells are transduced using HSV1-TK-based imaging [cxxix].

It would be necessary to immunosuppress the patient during the vector envelope biomolecular/capsid degradation stage. The gene vectors could inducibly self-cleave when the treatment is complete - to avoid any immunological issues after

immunosuppression is ceased - unless long-term episomal maintenance is desired. Also, an innate immune dsDNA sensor has been discovered that can detect foreign genomes [cxxx]. However, a seemingly non-immunogenic HSV-1 vector has been designed [ , -immunogenic *in vivo*, it could help. This variant was also essentially non-leaky - but only in a single cell type. Further alterations like those mentioned here [ - even with elements like the one cited here [ -cleave after treatment, but dsDNA fragments could integrate into the target cell genomes. (When more is known about nucleophagy, we could potentially induce the vector to bud in a micronucleus to be disposed of through macroautophagy - if not too many proteins are required [ ])

Using magnetotactic macrophages, the majority of the thymus could first be transduced by the vector, allowing for immune tolerance to the constitutively-expressed viral protein or proteins that allow for periodic induction of lipofuscin export [cxxxvii]. T-cells should first be depleted in the patient, though. Perhaps the gene vector can incorporate elements such as ICP47, a MHC class I inhibitor [ -cell-related reaction. If all the induced proteins are unaltered endogenous proteins, this obviously won't be an issue. Possibly, the inducible proteins can be expressed at low levels constitutively in the thymus, allowing for immune tolerance to them as well - perhaps with degrons to prevent their normal effects but allow for antigenic processing by the proteasome. This would be ideal, to avoid the possibility of an immune reaction if the induction system is slightly leaky in some cell types *in vivo*.

Once the lipofuscin is exported - either systemically via small molecule or perhaps locale by locale with the system referenced here [cxxxix] - one would sweep each anatomical region with more magnetotactic macrophages to pick up the garbage. If secretory autophagy or microvesicular secretion is employed, ideally the outermost membrane can be marked in such a way as to make it a clear target for the macrophages. Then, once they are likely full, they will be guided to the intraperitoneal extraction point. Given how difficult it would be to install the gene vector in every cell in the body that needs treatment, it would be best if we could leave it in our cells - to be induced perhaps every decade starting at ~30 years of age.

This viral vector strategy is also applicable as a means of treating genetic illness. Of course, in the future, if we can figure out how to induce systemic extravasation of bioengineered leukocytes without severe inflammation - it would be even better. The viral vector could deliver CRISPR components to target cells. Additionally, the leukocytes could protect our cells against viral infections by secreting a gene vector encoding double-stranded RNA-activated caspase oligomerizer (DRACO) [cxl] - or they could be used for treatment and simply secrete the DRACOs themselves.

Perhaps the viral strategy would be best for now - until we can rely on systemic extravasation - and then we can simply deliver the phagocytic, magnetotactic bacteria to target cells throughout the body and clear out the lipofuscin in a straightforward manner that is completely transient. In other words, it would not leave all of us with a gene vector in all of our (non-dividing) cells. The viral strategy also would not help with cells that divide slowly or infrequently, either - unless we integrate the vector DNA into the cells' genomes using a CRISPR-associated transposase [cxli], for example. Alternatively, the vector DNA could replicate a small amount, employing the aforementioned plasmid copy number control system. Or, an S/MAR could be utilized [ ].

---

Together, I call both phagocytic microbe-dependent and phagocytic microbe-independent *in vivo* lipofuscin removal approaches, “Clearance of Undigested Rubbish by Encapsulation” (CURE). That is because regardless of how the lipofuscin is ejected from post-mitotic cells, it ends up in a bioengineered leukocyte that will at some point migrate to an extraction point.

**Conclusion:**

Through synthetic biology, I believe we can clear lipofuscin from our tissues. There is a research article showing that TFEB overexpression can shrink lipofuscin deposits - but this work was done in the context of a transgenic mouse model with overproduction of an aggregating protein, which I would define as “false” lipofuscin [cxliiii]. Namely, if the protein ceased to already completely overwhelmed, it could be degraded over a reasonable amount of time by endogenous lysosomal hydrolases.

As we have never really had a way to clear true heterogeneous, age-related lipofuscin from our cells - it would be extremely interesting to put the “garbage catastrophe theory of aging” to the test with new techniques.

**Ethics approval and consent to participate:**

N/A

**Consent for publication:**

N/A

**Availability of data and material:**

N/A

**Competing interests:**

The author declares that he has no competing interests.

**Funding:**

Funding not received for the study.

**Authors' contributions:**

M.R. wrote the paper.

**Acknowledgements:**

I would like to thank Dr. Aubrey de Grey - as well as Michael Rae - for their work on anti-aging. Through Dr. Aubrey de Grey's 2005 TED talk and his book with Michael Rae, I was introduced to the concept of lipofuscin. Thank you to my family and Sid Verma for very helpful conversations. Finally, I am grateful to Dr. Joseph C. Glorioso III for his personal correspondence. The figures in this piece were created with BioRender.com.

**References:**

- 
- <sup>i</sup> Zealley B, de Grey ADNJ. Strategies for Engineered Negligible Senescence. *Gerontology* (2013) 59:183–189. doi:[10.1159/000342197](https://doi.org/10.1159/000342197)
- <sup>ii</sup> Siebert S, Farrell JA, Cazet JF, et al. Stem Cell Differentiation Trajectories in Hydra Resolved at Single-Cell Resolution. *Science* 2019;365(6451):eaav9314; doi: [10.1126/science.aav9314](https://doi.org/10.1126/science.aav9314).
- <sup>iii</sup> Murad R, Macias-Muñoz A, Wong A, et al. Coordinated Gene Expression and Chromatin Regulation during Hydra Head Regeneration. *Genome Biology and Evolution* 2021;13(12):evab221; doi: [10.1093/gbe/evab221](https://doi.org/10.1093/gbe/evab221).
- <sup>iv</sup> Terman A, Brunk UT. Is aging the price for memory? *Biogerontology* (2005) 6:205–210. doi:[10.1007/s10522-005-7956-3](https://doi.org/10.1007/s10522-005-7956-3)
- <sup>v</sup> Klapper W, Kühne K, Singh KK, Heidorn K, Parwaresch R, Krupp G. Longevity of lobsters is linked to ubiquitous telomerase expression. *FEBS Letters* (1998) 439:143–146. doi: [10.1016/S0014-5793\(98\)01357-X](https://doi.org/10.1016/S0014-5793(98)01357-X)
- <sup>vi</sup> Beltz BS, Sandeman DC. Regulation of life-long neurogenesis in the decapod crustacean brain. *Arthropod Structure & Development* (2003) 32:39–60. doi: [10.1016/S1467-8039\(03\)00038-0](https://doi.org/10.1016/S1467-8039(03)00038-0)
- <sup>vii</sup> Peregrin I. Why we age — a new evolutionary view. *Biologia* (2017) 72:475–485. doi: [10.1515/biolog-2017-0064](https://doi.org/10.1515/biolog-2017-0064)
- <sup>viii</sup> Sheehy M, Shelton P, Wickins J, Belchier M, Gaten E. Ageing the European lobster *Homarus gammarus* by the lipofuscin in its eyestalk ganglia. *Mar Ecol Prog Ser* (1996) 143:99–111. doi: [10.3354/meps143099](https://doi.org/10.3354/meps143099)
- <sup>ix</sup> Kakimoto Y, Okada C, Kawabe N, Sasaki A, Tsukamoto H, Nagao R, Osawa M. Myocardial lipofuscin accumulation in ageing and sudden cardiac death. *Sci Rep* (2019) 9:3304. doi:[10.1038/s41598-019-40250-0](https://doi.org/10.1038/s41598-019-40250-0)
- <sup>x</sup> Karavanich C, Atema J. Individual recognition and memory in lobster dominance. *Animal Behaviour* (1998) 56:1553–1560. doi:[10.1006/anbe.1998.0914](https://doi.org/10.1006/anbe.1998.0914)
- <sup>xi</sup> Zhao S, Lin L, Kan G, Xu C, Tang Q, Yu C, Sun W, Cai L, Xu C, Cui S. High autophagy in the naked mole rat may play a significant role in maintaining good health. *Cell Physiol Biochem* (2014) 33:321–332. doi: [10.1159/000356672](https://doi.org/10.1159/000356672)
- <sup>xii</sup> Triplett JC, Tramutola A, Swomley A, Kirk J, Grimes K, Lewis K, Orr M, Rodriguez K, Cai J, Klein JB, et al. Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* (2015) 1852:2213–2224. doi: [10.1016/j.bbadis.2015.08.002](https://doi.org/10.1016/j.bbadis.2015.08.002)
- <sup>xiii</sup> Hadi F, Kulaberoglu Y, Lazarus KA, Bach K, Ugur R, Beattie P, Smith ESJ, Khaled WT. Transformation of naked mole-rat cells. *Nature* (2020) 583:E1–E7. doi: [10.1038/s41586-020-2410-x](https://doi.org/10.1038/s41586-020-2410-x)
- <sup>xiv</sup> Edrey YH, Hanes M, Pinto M, Mele J, Buffenstein R. Successful aging and sustained good health in the naked mole rat: a long-lived mammalian model for biogerontology and biomedical research. *ILAR J* (2011) 52:41–53. doi: [10.1093/ilar.52.1.41](https://doi.org/10.1093/ilar.52.1.41)
- <sup>xv</sup> Panno JP, Nair KK. Effects of increased lifespan on chromatin condensation in the adult male housefly. *Mech Ageing Dev* (1986) 35:31–38. doi: [10.1016/0047-6374\(86\)90063-1](https://doi.org/10.1016/0047-6374(86)90063-1)
- <sup>xvi</sup> Clokey GV, Jacobson LA. The autofluorescent “lipofuscin granules” in the intestinal cells of *Caenorhabditis elegans* are secondary lysosomes. *Mech Ageing Dev* (1986) 35:79–94. doi: [10.1016/0047-6374\(86\)90068-0](https://doi.org/10.1016/0047-6374(86)90068-0)
- <sup>xvii</sup> Houthoofd K, Braeckman BP, Lenaerts I, Brys K, De Vreese A, Van Eygen S, Vanfleteren JR. Ageing is reversed, and metabolism is reset to young levels in recovering dauer larvae of *C. elegans*. *Exp Gerontol* (2002) 37:1015–1021. doi: [10.1016/s0531-5565\(02\)00063-3](https://doi.org/10.1016/s0531-5565(02)00063-3)
- <sup>xviii</sup> Goyal VK. Lipofuscin pigment accumulation in the central nervous system of the mouse during aging. *Exp Gerontol* (1982) 17:89–94. doi: [10.1016/0531-5565\(82\)90041-9](https://doi.org/10.1016/0531-5565(82)90041-9)
- <sup>xix</sup> Gilissen EP, Staneva-Dobrovski L. Distinct Types of Lipofuscin Pigment in the Hippocampus and Cerebellum of Aged Cheirogaleid Primates. *The Anatomical Record* (2013) 296:1895–1906. doi: [10.1002/ar.22809](https://doi.org/10.1002/ar.22809)

- 
- <sup>xx</sup> Moreno-García A, Kun A, Calero O, Medina M, Calero M. An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. *Frontiers in Neuroscience* (2018) **12**: <https://www.frontiersin.org/article/10.3389/fnins.2018.00464> [Accessed March 31, 2022]
- <sup>xxi</sup> Gray DA and Woulfe J. Lipofuscin and Aging: A Matter of Toxic Waste. *Science of Aging Knowledge Environment* 2005;2005(5):re1–re1; doi: [10.1126/sageke.2005.5.re1](https://doi.org/10.1126/sageke.2005.5.re1).
- <sup>xxii</sup> Terman A, Brunk UT. Is Lipofuscin Eliminated from Cells? *Investigative Ophthalmology & Visual Science* (1999) **40**:2463–2464.
- <sup>xxiii</sup> Julien S, Schraermeyer U. Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys. *Neurobiol Aging* (2012) **33**:2390–2397. doi: [10.1016/j.neurobiolaging.2011.12.009](https://doi.org/10.1016/j.neurobiolaging.2011.12.009)
- <sup>xxiv</sup> O’Neil SM, Witcher KG, McKim DB, Godbout JP. Forced turnover of aged microglia induces an intermediate phenotype but does not rebalance CNS environmental cues driving priming to immune challenge. *Acta Neuropathologica Communications* (2018) **6**:129. doi: [10.1186/s40478-018-0636-8](https://doi.org/10.1186/s40478-018-0636-8)
- <sup>xxv</sup> Burns JC, Cotleur B, Walther DM, Bajrami B, Rubino SJ, Wei R, Franchimont N, Cotman SL, Ransohoff RM, Mingueneau M. Differential accumulation of storage bodies with aging defines discrete subsets of microglia in the healthy brain. *eLife* (2020) **9**:e57495. doi: [10.7554/eLife.57495](https://doi.org/10.7554/eLife.57495)
- <sup>xxvi</sup> Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. *Free Radic Biol Med* (2002) **33**:611–619. doi: [10.1016/s0891-5849\(02\)00959-0](https://doi.org/10.1016/s0891-5849(02)00959-0)
- <sup>xxvii</sup> Pan C, Banerjee K, Lehmann GL, et al. Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization. *Proceedings of the National Academy of Sciences* 2021;118(47):e2100122118; doi: [10.1073/pnas.2100122118](https://doi.org/10.1073/pnas.2100122118).
- <sup>xxviii</sup> Terman A, Dalen H, Brunk UT. Ceroid/lipofuscin-loaded human fibroblasts show decreased survival time and diminished autophagocytosis during amino acid starvation☆. *Experimental Gerontology* 1999;34(8):943–957; doi: [10.1016/S0531-5565\(99\)00070-4](https://doi.org/10.1016/S0531-5565(99)00070-4).
- <sup>xxix</sup> Seluanov A, Gladyshev VN, Vijg J, et al. Mechanisms of cancer resistance in long-lived mammals. *Nat Rev Cancer* 2018;18(7):433–441; doi: [10.1038/s41568-018-0004-9](https://doi.org/10.1038/s41568-018-0004-9).
- <sup>xxx</sup> Samorajski T, Ordy JM, Rady-Reimer P. Lipofuscin pigment accumulation in the nervous system of aging mice. *The Anatomical Record* (1968) **160**:555–573. doi: [10.1002/ar.1091600305](https://doi.org/10.1002/ar.1091600305)
- <sup>xxxi</sup> Brizzee KR, Johnson FA. Depth distribution of lipofuscin pigment in cerebral cortex of albino rat. *Acta Neuropathol* (1970) **16**:205–219. doi: [10.1007/BF00687360](https://doi.org/10.1007/BF00687360)
- <sup>xxxii</sup> Yanai S, Endo S. Functional Aging in Male C57BL/6J Mice Across the Life-Span: A Systematic Behavioral Analysis of Motor, Emotional, and Memory Function to Define an Aging Phenotype. *Frontiers in Aging Neuroscience* 2021;13.
- <sup>xxxiii</sup> Lutz CM, Osborne MA. Optimizing mouse models of neurodegenerative disorders: are therapeutics in sight? *Future Neurology* 2014;9(1):67–75; doi: [10.2217/fnl.13.66](https://doi.org/10.2217/fnl.13.66).
- <sup>xxxiv</sup> Double KL, Dedov VN, Fedorow H, et al. The comparative biology of neuromelanin and lipofuscin in the human brain. *Cell Mol Life Sci* 2008;65(11):1669–1682; doi: [10.1007/s00018-008-7581-9](https://doi.org/10.1007/s00018-008-7581-9).
- <sup>xxxv</sup> Mann DM, Yates PO, Stamp JE. The relationship between lipofuscin pigment and ageing in the human nervous system. *J Neurol Sci* (1978) **37**:83–93. doi: [10.1016/0022-510x\(78\)90229-0](https://doi.org/10.1016/0022-510x(78)90229-0)
- <sup>xxxvi</sup> Goyal VK. Lipofuscin pigment accumulation in human brain during aging. *Experimental Gerontology* 1982;17(6):481–487; doi: [10.1016/S0531-5565\(82\)80010-7](https://doi.org/10.1016/S0531-5565(82)80010-7).
- <sup>xxxvii</sup> Benavides SH, Monserrat AJ, Fariña S, et al. Sequential histochemical studies of neuronal lipofuscin in human cerebral cortex from the first to the ninth decade of life. *Archives of Gerontology and Geriatrics* 2002;34(3):219–231; doi: [10.1016/S0167-4943\(01\)00223-0](https://doi.org/10.1016/S0167-4943(01)00223-0).

- xxxviii Yin D. Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. *Free Radical Biology and Medicine* 1996;21(6):871–888; doi: [10.1016/0891-5849\(96\)00175-X](https://doi.org/10.1016/0891-5849(96)00175-X).
- xxxix Wing GL, Blanchard GC, Weiter JJ. The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium. *Investigative Ophthalmology & Visual Science* (1978) **17**:601–607.
- xl Dayan D, Abrahami I, Buchner A, Gorsky M, Chimovitz N. Lipid pigment (lipofuscin) in human perioral muscles with aging. *Experimental Gerontology* (1988) **23**:97–102. doi: [10.1016/0531-5565\(88\)90074-5](https://doi.org/10.1016/0531-5565(88)90074-5)
- xli Xu H, Ren D. Lysosomal Physiology. *Annu Rev Physiol* (2015) **77**:57–80. doi: [10.1146/annurev-physiol-021014-071649](https://doi.org/10.1146/annurev-physiol-021014-071649)
- xliv Kakimoto Y, Okada C, Kawabe N, Sasaki A, Tsukamoto H, Nagao R, Osawa M. Myocardial lipofuscin accumulation in ageing and sudden cardiac death. *Sci Rep* (2019) **9**:3304. doi: [10.1038/s41598-019-40250-0](https://doi.org/10.1038/s41598-019-40250-0)
- lv Jaffer FA, Blankstein R. Getting Down With Diet and Exercise for Coronary Artery Disease Treatment. *JACC: Cardiovascular Imaging* (2021) **14**:1203–1205. doi: [10.1016/j.jcmg.2021.01.003](https://doi.org/10.1016/j.jcmg.2021.01.003)
- lvi Idrobo F, Nandy K, Mostofsky DI, Blatt L, Nandy L. Dietary restriction: effects on radial maze learning and lipofuscin pigment deposition in the hippocampus and frontal cortex. *Archives of Gerontology and Geriatrics* (1987) **6**:355–362. doi: [10.1016/0167-4943\(87\)90014-8](https://doi.org/10.1016/0167-4943(87)90014-8)
- lvii Chung KW, Chung HY. The Effects of Calorie Restriction on Autophagy: Role on Aging Intervention. *Nutrients* (2019) **11**:2923. doi: [10.3390/nu1122923](https://doi.org/10.3390/nu1122923)
- lviii Subramanyam MVV. Dietary vitamin E and physical exercise: II. Antioxidant status and lipofuscin-like substances in aging rat heart. [https://core.ac.uk/reader/72797312?utm\\_source=linkout](https://core.ac.uk/reader/72797312?utm_source=linkout) [Accessed April 5, 2022]
- lix de Grey A, Rae M, (eds). ENDING AGING: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime. St. Martin's Press: U.S.; 2007.
- lx de Grey AD. Appropriating Microbial Catabolism: A Proposal to Treat and Prevent Neurodegeneration. *Neurobiology of aging* 2006;27(4):589–595.
- lxi Boellaard JW and Schlote W. Ultrastructural Heterogeneity of Neuronal Lipofuscin in the Normal Human Cerebral Cortex. *Acta Neuropathol* 1986;71(3–4):285–294; doi: [10.1007/BF00688051](https://doi.org/10.1007/BF00688051).
- <sup>1</sup> Sparrow JR, Parish CA, Hashimoto M, et al. A2E, a Lipofuscin Fluorophore, in Human Retinal Pigmented Epithelial Cells in Culture. *Investigative Ophthalmology & Visual Science* 1999;40(12):2988–2995.
- <sup>ii</sup> Anderson A, Campo A, Fulton E, et al. 7-Ketocholesterol in Disease and Aging. *Redox Biology* 2020;29:101380; doi: [10.1016/j.redox.2019.101380](https://doi.org/10.1016/j.redox.2019.101380).
- <sup>iii</sup> Lapierre LR, De Magalhaes Filho CD, McQuary PR, Chu C-C, Visvikis O, Chang JT, Gelino S, Ong B, Davis AE, Irazoqui JE, et al. The TFEB orthologue HLH-30 regulates autophagy and modulates longevity in *Caenorhabditis elegans*. *Nat Commun* (2013) **4**:2267. doi: [10.1038/ncomms3267](https://doi.org/10.1038/ncomms3267)
- <sup>liii</sup> Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells. *Journal of Cell Biology* (2002) **159**:625–635. doi: [10.1083/jcb.200208154](https://doi.org/10.1083/jcb.200208154)
- <sup>liii</sup> Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spanpanato C, Puri C, Pignata A, Martina JA, Sardiello M, et al. Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance. *Dev Cell* (2011) **21**:421–430. doi: [10.1016/j.devcel.2011.07.016](https://doi.org/10.1016/j.devcel.2011.07.016)
- <sup>lv</sup> Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. *The EMBO Journal* (2013) **32**:2336–2347. doi: [10.1038/emboj.2013.171](https://doi.org/10.1038/emboj.2013.171)
- <sup>lvi</sup> Martinelli S, Anderzhanova EA, Bajaj T, Wiechmann S, Dethloff F, Weckmann K, Heinz DE, Ebert T, Hartmann J, Geiger TM, et al. Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion. *Nat Commun* (2021) **12**:4643. doi: [10.1038/s41467-021-24810-5](https://doi.org/10.1038/s41467-021-24810-5)

- lvii Florey O, Kim SE, Sandoval CP, Haynes CM, Overholtzer M. Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes. *Nat Cell Biol* (2011) **13**:1335–1343. doi: [10.1038/ncb2363](https://doi.org/10.1038/ncb2363)
- lviii Shiratori T, Suzuki S, Kakizawa Y, Ishida K. Phagocytosis-like cell engulfment by a planctomycete bacterium. *Nat Commun* (2019) **10**:5529. doi: [10.1038/s41467-019-13499-2](https://doi.org/10.1038/s41467-019-13499-2)
- lix Mylnikov AP, Weber F, Jürgens K, Wylezich C. Massisteria marina has a sister: Massisteria voersi sp. nov., a rare species isolated from coastal waters of the Baltic Sea. *Eur J Protistol* (2015) **51**:299–310. doi: [10.1016/j.ejop.2015.05.002](https://doi.org/10.1016/j.ejop.2015.05.002)
- lx Cesar S, Huang KC. Thinking big: the tunability of bacterial cell size. *FEMS Microbiology Reviews* 2017;41(5):672–678; doi: [10.1093/femsre/fux026](https://doi.org/10.1093/femsre/fux026).
- lxi Friedland AE, Lu TK, Wang X, Shi D, Church G, Collins JJ. Synthetic Gene Networks that Count. *Science* (2009) **324**:1199–1202. doi: [10.1126/science.1172005](https://doi.org/10.1126/science.1172005)
- lxii Yoon, Y. G. & Koob, M. D. Nonreplicating Intracellular Bacterial Vector for Conjugative DNA Transfer into Mitochondria. *Pharm Res* **29**, 1040–1045 (2012).
- lxiii Dutta, N. K. *et al.* Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence. *Science Advances* **5**, eaav2104 (2019).
- lxiv Sinha, A. K. & Winther, K. S. The RelA hydrolase domain acts as a molecular switch for (p)ppGpp synthesis. *Commun Biol* **4**, 1–10 (2021).
- lxv Schreiber, G. *et al.* Overexpression of the relA gene in Escherichia coli. *J Biol Chem* **266**, 3760–3767 (1991).
- lxvi Taylor, C. M. *et al.* Listeria monocytogenes relA and hpt mutants are impaired in surface-attached growth and virulence. *J Bacteriol* **184**, 621–628 (2002).
- lxvii Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. *Nat Biotechnol* (1998) **16**:862–866. doi: [10.1038/nbt0998-862](https://doi.org/10.1038/nbt0998-862)
- lxviii Yi J, Schmidt J, Chien A, Montemagno CD. Engineering an artificial amoeba propelled by nanoparticle-triggered actin polymerization. *Nanotechnology* (2009) **20**:085101. doi: [10.1088/0957-4484/20/8/085101](https://doi.org/10.1088/0957-4484/20/8/085101)
- lxix Bilbao G, Contreras JL, Zhang H-G, Pike MJ, Overturf K, Mikheeva G, Krasnykh V, Curiel DT. Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene. *Journal of virology* (1999) **73**:6992–7000.
- lxx Xu X, Pan M, Jin T. How Phagocytes Acquired the Capability of Hunting and Removing Pathogens From a Human Body: Lessons Learned From Chemotaxis and Phagocytosis of Dictyostelium discoideum (Review). *Frontiers in Cell and Developmental Biology* (2021) **9**: <https://www.frontiersin.org/article/10.3389/fcell.2021.724940> [Accessed April 15, 2022]
- lxxi Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. *Cell* (2016) **164**:780–791. doi: [10.1016/j.cell.2016.01.012](https://doi.org/10.1016/j.cell.2016.01.012)
- lxxii Ortega FE, Koslover EF, Theriot JA. Listeria monocytogenes cell-to-cell spread in epithelia is heterogeneous and dominated by rare pioneer bacteria. Garrett WS, Orth K, Slauch J, et al. eds. *eLife* 2019;8:e40032; doi: [10.7554/eLife.40032](https://doi.org/10.7554/eLife.40032).
- lxxiii Fliieger A, Frischknecht F, Häcker G, et al. Pathways of host cell exit by intracellular pathogens. *Microbial Cell* 2018;5(12):525–544; doi: [10.15698/mic2018.12.659](https://doi.org/10.15698/mic2018.12.659).
- lxxiv Checroun C, Wehrly TD, Fischer ER, et al. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. *Proceedings of the National Academy of Sciences* 2006;103(39):14578–14583; doi: [10.1073/pnas.0601838103](https://doi.org/10.1073/pnas.0601838103).
- lxxv Chai Q, Wang X, Qiang L, et al. A Mycobacterium tuberculosis surface protein recruits ubiquitin to trigger host xenophagy. *Nature Communications* 2019;10(1):1973; doi: [10.1038/s41467-019-09955-8](https://doi.org/10.1038/s41467-019-09955-8).
- lxxvi Cheng MI, Chen C, Engström P, et al. Actin-based motility allows Listeria monocytogenes to avoid autophagy in the macrophage cytosol. *Cell Microbiol* 2018;20(9):e12854; doi: [10.1111/cmi.12854](https://doi.org/10.1111/cmi.12854).

- <sup>lxxvii</sup> Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, Kim M, Mimuro H, Nakagawa I, Yanagawa T, Ishii T, et al. *Listeria monocytogenes* ActA-mediated escape from autophagic recognition. *Nat Cell Biol* (2009) 11:1233–1240. doi:[10.1038/ncb1967](https://doi.org/10.1038/ncb1967)
- <sup>lxxviii</sup> Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, Schneider DS, Nakamura K, Shiloh MU, Cox JS. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. *Nature* (2013) 501:512–516. doi:[10.1038/nature12566](https://doi.org/10.1038/nature12566)
- <sup>lxxix</sup> Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, Foreman O, Kirkpatrick DS, Sheng M. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature* (2014) 510:370–375. doi:[10.1038/nature13418](https://doi.org/10.1038/nature13418)
- <sup>lxxx</sup> Torra A, Parent A, Cuadros T, Rodríguez-Galván B, Ruiz-Bronchal E, Ballabio A, Bortolozzi A, Vila M, Bové J. Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson’s Disease-Related Neurodegeneration. *Mol Ther* (2018) 26:1552–1567. doi: [10.1016/j.ymthe.2018.02.022](https://doi.org/10.1016/j.ymthe.2018.02.022)
- <sup>lxxxi</sup> Li Z. “5.43 - In Vitro Micro-Tissue and -Organ Models for Toxicity Testing.,” In: Moo-Young M, editor. *Comprehensive Biotechnology (Second Edition)*. Burlington: Academic Press (2011). p. 551–563 doi: [10.1016/B978-0-08-088504-9.00503-1](https://doi.org/10.1016/B978-0-08-088504-9.00503-1)
- <sup>lxxxii</sup> Potter SM, DeMarse TB. A new approach to neural cell culture for long-term studies. *Journal of Neuroscience Methods* (2001) 110:17–24. doi: [10.1016/S0165-0270\(01\)00412-5](https://doi.org/10.1016/S0165-0270(01)00412-5)
- <sup>lxxxiii</sup> Dong W, Cheng S, Huang F, Fan W, Chen Y, Shi H, He H. Mitochondrial dysfunction in long-term neuronal cultures mimics changes with aging. *Med Sci Monit* (2011) 17:BR91–BR96. doi: [10.12659/MSM.881706](https://doi.org/10.12659/MSM.881706)
- <sup>lxxxiv</sup> Moreno-Blas D, Gorostieta-Salas E, Pommer-Alba A, Muciño-Hernández G, Gerónimo-Olvera C, Maciel-Barón LA, Konigsberg M, Massieu L, Castro-Obregón S. Cortical neurons develop a senescence-like phenotype promoted by dysfunctional autophagy. *Aging (Albany NY)* (2019) 11:6175–6198. doi: [10.18632/aging.102181](https://doi.org/10.18632/aging.102181)
- <sup>lxxxv</sup> Triolo M, Hood DA. Manifestations of Age on Autophagy, Mitophagy and Lysosomes in Skeletal Muscle. *Cells* (2021) 10:1054. doi: [10.3390/cells10051054](https://doi.org/10.3390/cells10051054)
- <sup>lxxxvi</sup> Willett R, Martina JA, Zewe JP, Wills R, Hammond GRV, Puertollano R. TFEB regulates lysosomal positioning by modulating TMEM55B expression and JIP4 recruitment to lysosomes. *Nat Commun* (2017) 8:1580. doi: [10.1038/s41467-017-01871-z](https://doi.org/10.1038/s41467-017-01871-z)
- <sup>lxxxvii</sup> Tancini B, Buratta S, Delo F, et al. Lysosomal Exocytosis: The Extracellular Role of an Intracellular Organelle. *Membranes (Basel)* 2020;10(12):E406; doi: [10.3390/membranes10120406](https://doi.org/10.3390/membranes10120406).
- <sup>lxxxviii</sup> Wurmthaler LA, Sack M, Gense K, Hartig JS, Gamerdinger M. A tetracycline-dependent ribozyme switch allows conditional induction of gene expression in *Caenorhabditis elegans*. *Nat Commun* (2019) 10:491. doi: [10.1038/s41467-019-08412-w](https://doi.org/10.1038/s41467-019-08412-w)
- <sup>lxxxix</sup> Chauhan S, Kumar S, Jain A, et al. TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis. *Developmental Cell* 2016;39(1):13–27; doi: [10.1016/j.devcel.2016.08.003](https://doi.org/10.1016/j.devcel.2016.08.003).
- <sup>xc</sup> Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. *The EMBO Journal* (2017) 36:42–60. doi: [10.15252/embj.201695081](https://doi.org/10.15252/embj.201695081)
- <sup>xci</sup> Hoyer MJ, Swarup S, Wade Harper J. Mechanisms controlling selective elimination of damaged lysosomes. *Current Opinion in Physiology* 2022;29:100590; doi: [10.1016/j.cophys.2022.100590](https://doi.org/10.1016/j.cophys.2022.100590).
- <sup>xcii</sup> Vats S, Manjithaya R. A reversible autophagy inhibitor blocks autophagosome–lysosome fusion by preventing Stx17 loading onto autophagosomes. *MBoC* 2019;30(17):2283–2295; doi: [10.1091/mbc.E18-08-0482](https://doi.org/10.1091/mbc.E18-08-0482).
- <sup>xciii</sup> Solvik TA, Nguyen TA, Tony Lin Y-H, et al. Secretory autophagy maintains proteostasis upon lysosome inhibition. *Journal of Cell Biology* 2022;221(6):e202110151; doi: [10.1083/jcb.202110151](https://doi.org/10.1083/jcb.202110151).

- <sup>xciv</sup> Schweers RL, Zhang J, Randall MS, et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. *Proc Natl Acad Sci U S A* 2007;104(49):19500–19505; doi: [10.1073/pnas.0708818104](https://doi.org/10.1073/pnas.0708818104).
- <sup>xcv</sup> Takenouchi T, Nakai M, Iwamaru Y, et al. The Activation of P2X7 Receptor Impairs Lysosomal Functions and Stimulates the Release of Autophagolysosomes in Microglial Cells. *The Journal of Immunology* 2009;182(4):2051–2062; doi: [10.4049/jimmunol.0802577](https://doi.org/10.4049/jimmunol.0802577).
- <sup>xcvi</sup> Birgisdottir ÅB, Lamark T, Johansen T. The LIR motif - crucial for selective autophagy. *J Cell Sci* 2013;126(Pt 15):3237–3247; doi: [10.1242/jcs.126128](https://doi.org/10.1242/jcs.126128).
- <sup>xcvii</sup> English JG, Olsen RHJ, Lansu K, et al. VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells. *Cell* 2019;178(3):748–761.e17; doi: [10.1016/j.cell.2019.05.051](https://doi.org/10.1016/j.cell.2019.05.051).
- <sup>xcviii</sup> Reinke AW, Grant RA, Keating AE. A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering. *J Am Chem Soc* 2010;132(17):6025–6031; doi: [10.1021/ja907617a](https://doi.org/10.1021/ja907617a).
- <sup>xcix</sup> Gäbelein CG, Feng Q, Sarajlic E, Zambelli T, Guillaume-Gentil O, Kornmann B, Vorholt JA. Mitochondria transplantation between living cells. *PLOS Biology* (2022) 20:e3001576. doi: [10.1371/journal.pbio.3001576](https://doi.org/10.1371/journal.pbio.3001576)
- <sup>c</sup> Kolinko I, Lohße A, Borg S, et al. Biosynthesis of magnetic nanostructures in a foreign organism by transfer of bacterial magnetosome gene clusters. *Nat Nanotechnol* 2014;9(3):193–197; doi: [10.1038/nnano.2014.13](https://doi.org/10.1038/nnano.2014.13).
- <sup>ci</sup> Muthana M, Kennerley AJ, Hughes R, et al. Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. *Nature Communications* 2015;6(1):8009; doi: [10.1038/ncomms9009](https://doi.org/10.1038/ncomms9009).
- <sup>cii</sup> Han J, Zhen J, Du Nguyen V, et al. Hybrid-Actuating Macrophage-Based Microrobots for Active Cancer Therapy. *Scientific Reports* 2016;6(1):28717; doi: [10.1038/srep28717](https://doi.org/10.1038/srep28717).
- <sup>ciii</sup> Harimoto T, Hahn J, Chen Y-Y, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. *Nat Biotechnol* 2022;40(8):1259–1269; doi: [10.1038/s41587-022-01244-y](https://doi.org/10.1038/s41587-022-01244-y).
- <sup>civ</sup> Reniere ML, Whiteley AT, Hamilton KL, et al. Glutathione activates virulence gene expression of an intracellular pathogen. *Nature* 2015;517(7533):170–173; doi: [10.1038/nature14029](https://doi.org/10.1038/nature14029).
- <sup>cv</sup> Gedde MM, Higgins DE, Tilney LG, et al. Role of Listeriolysin O in Cell-to-Cell Spread of *Listeria monocytogenes*. *Infect Immun* 2000;68(2):999–1003.
- <sup>cvi</sup> Le Nagard L, Brown AT, Dawson A, et al. Encapsulated bacteria deform lipid vesicles into flagellated swimmers. *Proceedings of the National Academy of Sciences* 2022;119(34):e2206096119; doi: [10.1073/pnas.2206096119](https://doi.org/10.1073/pnas.2206096119).
- <sup>cvi</sup> Uebe R, Schüler D. Magnetosome biogenesis in magnetotactic bacteria. *Nat Rev Microbiol* 2016;14(10):621–637; doi: [10.1038/nrmicro.2016.99](https://doi.org/10.1038/nrmicro.2016.99).
- <sup>cvi</sup> Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, Vale RD. Chimeric antigen receptors that trigger phagocytosis. *eLife* (2018) 7:e36688. doi: [10.7554/eLife.36688](https://doi.org/10.7554/eLife.36688)
- <sup>cix</sup> Park JS, Rhau B, Hermann A, McNally KA, Zhou C, Gong D, Weiner OD, Conklin BR, Onuffer J, Lim WA. Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. *Proc Natl Acad Sci USA* (2014) 111:5896–5901. doi: [10.1073/pnas.1402087111](https://doi.org/10.1073/pnas.1402087111)
- <sup>cx</sup> Stritzker J, Hill PJ, Gentschev I, et al. Myristoylation negative msbB-mutants of probiotic *E. coli* Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. *Bioeng Bugs* 2010;1(2):139–145; doi: [10.4161/bbug.1.2.10286](https://doi.org/10.4161/bbug.1.2.10286).
- <sup>cx</sup> García-Cao I, García-Cao M, Martín-Caballero J, et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. *The EMBO Journal* 2002;21(22):6225–6235; doi: [10.1093/emboj/cdf595](https://doi.org/10.1093/emboj/cdf595).
- <sup>cxii</sup> Matheu A, Maraver A, Klatt P, et al. Delayed ageing through damage protection by the Arf/p53 pathway. *Nature* 2007;448(7151):375–379; doi: [10.1038/nature05949](https://doi.org/10.1038/nature05949).

- <sup>cxiii</sup> Zhao Y, Burikhanov R, Qiu S, et al. Cancer resistance in transgenic mice expressing the SAC module of Par-4. *Cancer Res* 2007;67(19):9276–9285; doi: [10.1158/0008-5472.CAN-07-2124](https://doi.org/10.1158/0008-5472.CAN-07-2124).
- <sup>cxiv</sup> Garcia-Cao I, Song MS, Hobbs RM, et al. Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State. *Cell* 2012;149(1):49–62; doi: [10.1016/j.cell.2012.02.030](https://doi.org/10.1016/j.cell.2012.02.030).
- <sup>cxv</sup> Reeves AZ, Spears WE, Du J, et al. Engineering Escherichia coli into a Protein Delivery System for Mammalian Cells. *ACS Synth Biol* 2015;4(5):644–654; doi: [10.1021/acssynbio.5b00002](https://doi.org/10.1021/acssynbio.5b00002).
- <sup>cxvi</sup> Gupta M, Shin D-M, Ramakrishna L, et al. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of *Listeria monocytogenes*. *Nature Communications* 2015;6:6379; doi: [10.1038/ncomms7379](https://doi.org/10.1038/ncomms7379).
- <sup>cxvii</sup> Miller ST, Xavier KB, Campagna SR, Taga ME, Semmelhack MF, Bassler BL, Hughson FM. Salmonella typhimurium recognizes a chemically distinct form of the bacterial quorum-sensing signal AI-2. *Mol Cell* (2004) **15**:677–687. doi: [10.1016/j.molcel.2004.07.020](https://doi.org/10.1016/j.molcel.2004.07.020)
- <sup>cxviii</sup> Woodsworth DJ, Dreolini L, Abraham L, et al. Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway. *Mol Ther Methods Clin Dev* 2017;7:132–145; doi: [10.1016/j.omtm.2017.10.003](https://doi.org/10.1016/j.omtm.2017.10.003).
- <sup>cxix</sup> Hase K, Kimura S, Takatsu H, et al. M-Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex. *Nat Cell Biol* 2009;11(12):1427–1432; doi: [10.1038/ncb1990](https://doi.org/10.1038/ncb1990).
- <sup>cxx</sup> Schiller C, Diakopoulos KN, Rohwedder I, et al. LST1 promotes the assembly of a molecular machinery responsible for tunneling nanotube formation. *Journal of Cell Science* 2013;126(3):767–777; doi: [10.1242/jcs.114033](https://doi.org/10.1242/jcs.114033).
- <sup>cxxi</sup> Yang L, Zhang Y, Zhang Y, et al. Live Macrophage-Delivered Doxorubicin-Loaded Liposomes Effectively Treat Triple-Negative Breast Cancer. *ACS Nano* 2022;16(6):9799–9809; doi: [10.1021/acsnano.2c03573](https://doi.org/10.1021/acsnano.2c03573).
- <sup>cxixi</sup> Yu S, Yang H, Li T, et al. Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. *Nat Commun* 2021;12(1):5131; doi: [10.1038/s41467-021-25448-z](https://doi.org/10.1038/s41467-021-25448-z).
- <sup>cxixiii</sup> Verdurmen WPR, Mazlami M, Plückthun A. A quantitative comparison of cytosolic delivery via different protein uptake systems. *Sci Rep* 2017;7(1):13194; doi: [10.1038/s41598-017-13469-y](https://doi.org/10.1038/s41598-017-13469-y).
- <sup>cxixiv</sup> Allen WE, Zicha D, Ridley AJ, et al. A Role for Cdc42 in Macrophage Chemotaxis. *Journal of Cell Biology* 1998;141(5):1147–1157; doi: [10.1083/jcb.141.5.1147](https://doi.org/10.1083/jcb.141.5.1147).
- <sup>cxixv</sup> Okibe N, Suzuki N, Inui M, Yukawa H. Antisense-RNA-mediated plasmid copy number control in pCG1-family plasmids, pCGR2 and pCG1, in *Corynebacterium glutamicum*. *Microbiology* (2010) **156**:3609–3623. doi: [10.1099/mic.0.043745-0](https://doi.org/10.1099/mic.0.043745-0)
- <sup>cxixvi</sup> Caussinus E, Kanca O, Affolter M. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. *Nature Structural & Molecular Biology* (2012) **19**:117–121. doi: [10.1038/nsmb.2180](https://doi.org/10.1038/nsmb.2180)
- <sup>cxixvii</sup> Horan KA, Hansen K, Jakobsen MR, Holm CK, Søbø S, Unterholzner L, Thompson M, West JA, Iversen MB, Rasmussen SB, et al. Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors. *J Immunol* (2013) **190**:2311–2319. doi: [10.4049/jimmunol.1202749](https://doi.org/10.4049/jimmunol.1202749)
- <sup>cxixviii</sup> Acar M, Pando BF, Arnold FH, Elowitz MB, van Oudenaarden A. A general mechanism for network-dosage compensation in gene circuits. *Science* (2010) **329**:1656–1660. doi: [10.1126/science.1190544](https://doi.org/10.1126/science.1190544)
- <sup>cxixix</sup> Johnson M, Karanikolas BDW, Priceman SJ, et al. Titration of Variant HSV1-tk Gene Expression to Determine the Sensitivity of 18F-FHBG PET Imaging in a Prostate Tumor. *J Nucl Med* 2009;50(5):757–764; doi: [10.2967/jnumed.108.058438](https://doi.org/10.2967/jnumed.108.058438).
- <sup>cxixx</sup> Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular DNA. *Nat Immunol* 2010;11(11):997–1004; doi: [10.1038/ni.1932](https://doi.org/10.1038/ni.1932).
- <sup>cxixxi</sup> Verlengia G, Miyagawa Y, Ingusci S, et al. Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. *Sci Rep* 2017;7(1):1507; doi: [10.1038/s41598-017-01635-1](https://doi.org/10.1038/s41598-017-01635-1).

- 
- <sup>xxxii</sup> Soukupová M, Zucchini S, Trempat P, et al. Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells. *Molecular Therapy - Methods & Clinical Development* 2021;21:399–412; doi: [10.1016/j.omtm.2021.03.020](https://doi.org/10.1016/j.omtm.2021.03.020).
- <sup>xxxiii</sup> Zaldumbide A, Weening S, Cramer SJ, et al. A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator. *Biotechnol Lett* 2010;32(6):749–754; doi: [10.1007/s10529-010-0218-8](https://doi.org/10.1007/s10529-010-0218-8).
- <sup>xxxiv</sup> Roney IJ, Rudner AD, Couture J-F, et al. Improvement of the reverse tetracycline transactivator by single amino acid substitutions that reduce leaky target gene expression to undetectable levels. *Sci Rep* 2016;6:27697; doi: [10.1038/srep27697](https://doi.org/10.1038/srep27697).
- <sup>xxxv</sup> Rudina SS, Smolke CD. A Novel Chromatin-Opening Element for Stable Long-Term Transgene Expression. 2019;626713; doi: [10.1101/626713](https://doi.org/10.1101/626713). **Preprint**.
- <sup>xxxvi</sup> Vo MT, Choi YB. Herpesvirus Regulation of Selective Autophagy. *Viruses* 2021;13(5):820; doi: [10.3390/v13050820](https://doi.org/10.3390/v13050820).
- <sup>xxxvii</sup> Nunes-Alves C, Nobrega C, Behar SM, et al. Tolerance has its limits: how the thymus copes with infection. *Trends Immunol* 2013;34(10); doi: [10.1016/j.it.2013.06.004](https://doi.org/10.1016/j.it.2013.06.004).
- <sup>xxxviii</sup> Shao W, Chen X, Samulski RJ, et al. Inhibition of antigen presentation during AAV gene therapy using virus peptides. *Hum Mol Genet* 2018;27(4):601–613; doi: [10.1093/hmg/ddx427](https://doi.org/10.1093/hmg/ddx427).
- <sup>xxxix</sup> Stanley SA, Gagner JE, Damanpour S, et al. Radio-Wave Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice. *Science* 2012;336(6081):604–608; doi: [10.1126/science.1216753](https://doi.org/10.1126/science.1216753).
- <sup>xl</sup> Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broad-Spectrum Antiviral Therapeutics. *PLOS ONE* (2011) 6:e22572. doi: [10.1371/journal.pone.0022572](https://doi.org/10.1371/journal.pone.0022572)
- <sup>xli</sup> Strecker J, Ladha A, Gardner Z, et al. RNA-guided DNA insertion with CRISPR-associated transposases. *Science* 2019;365(6448):48–53; doi: [10.1126/science.aax9181](https://doi.org/10.1126/science.aax9181).
- <sup>xlii</sup> Bozza M, Green EW, Espinet E, et al. Novel Non-integrating DNA Nano-S/MAR Vectors Restore Gene Function in Isogenic Patient-Derived Pancreatic Tumor Models. *Molecular Therapy - Methods & Clinical Development* 2020;17:957–968; doi: [10.1016/j.omtm.2020.04.017](https://doi.org/10.1016/j.omtm.2020.04.017).
- <sup>xliii</sup> Wang H, Wang R, Carrera I, et al. TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits. *eNeuro* 2016;3(2); doi: [10.1523/ENEURO.0042-16.2016](https://doi.org/10.1523/ENEURO.0042-16.2016).